Document Detail


The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance.
MedLine Citation:
PMID:  18001316     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The recent discoveries on the concerted role of several mechanisms involved in regulating the balance of body cholesterol highlight the role of intestinal absorption. Selective modulators of intestinal cholesterol absorption are available that offer a new pharmacologic approach to the modulation of total body cholesterol homeostasis and to a more effective reduction of low-density-lipoprotein cholesterol.
Authors:
Alberico L Catapano
Related Documents :
8257146 - Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.
16080306 - Incorporation of galactomannans in the diet of newly weaned piglets: effect on bacterio...
14642856 - Indications for specific therapy in the rehabilitation of patients with the short-bowel...
11591236 - Increasing viscosity of the intestinal contents alters small intestinal structure and i...
8402566 - Dose-related inhibition by dietary phenethyl isothiocyanate of esophageal tumorigenesis...
2361496 - Body mass index and body energy stores in developing countries.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  21 Suppl 2     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-16     Completed Date:  2008-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  21-6     Citation Subset:  IM    
Affiliation:
Center for the Study of Atherosclerosis and Laboratory of Lipoprotein Metabolism, Department of Pharmacological Sciences, University of Milan, Milan, Italy. alberico.catapano@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticholesteremic Agents / pharmacology*,  therapeutic use
Azetidines / pharmacology,  therapeutic use
Cholesterol / biosynthesis,  metabolism*,  pharmacokinetics
Homeostasis / drug effects*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use
Hypercholesterolemia / drug therapy,  metabolism
Intestinal Absorption / drug effects
Liver / drug effects,  metabolism
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Azetidines; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 163222-33-1/ezetimibe; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
Next Document:  Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.